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Alzheimer’s disease (AD) is the most common type of dementia, which has a substantial
genetic component. AD affects predominantly older people. Accordingly, the prevalence
of dementia has been rising as the population ages. To date, there are no effective
interventions that can cure or halt the progression of AD. The only available treatments
are the management of certain symptoms and consequences of dementia. The current
state-of-the-art medical care for AD comprises three simple principles: prevent the
preventable, achieve early diagnosis, and manage the manageable symptoms. This
review provides a summary of the current state of knowledge of risk factors for AD,
biological diagnostic testing, and prospects for treatment. Special emphasis is given to
recent advances in genetics of AD and the way genomic data may support prevention,
early intervention, and development of effective pharmacological treatments. Mutations
in the APP, PSEN1, and PSEN2 genes cause early onset Alzheimer’s disease (EOAD)
that follows a Mendelian inheritance pattern. For late onset Alzheimer’s disease (LOAD),
APOE4 was identified as a major risk allele more than two decades ago. Populationbased genome-wide association studies of late onset AD have now additionally identified
common variants at roughly 30 genetic loci. Furthermore, rare variants (allele frequency
<1%) that influence the risk for LOAD have been identified in several genes. These
genetic advances have broadened our insights into the biological underpinnings of AD.
Moreover, the known genetic risk variants could be used to identify presymptomatic
individuals at risk for AD and support diagnostic assessment of symptomatic subjects.
Genetic knowledge may also facilitate precision medicine. The goal of precision medicine
is to use biological knowledge and other health information to predict individual disease
risk, understand disease etiology, identify disease subcategories, improve diagnosis,
and provide personalized treatment strategies. We discuss the potential role of genetics
in advancing precision medicine for AD along with its ethical challenges. We outline
strategies to implement genomics into translational clinical research that will not only
improve accuracy of dementia diagnosis, thus enabling more personalized treatment
strategies, but may also speed up the discovery of novel drugs and interventions.
Keywords: Alzheimer’s disease, genetics, genomics, risk factors, risk variants, precision medicine, genome
sequencing
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INTRODUCTION

excluded. More recent scientifically rigorous and high-impact
studies on these topics that were found in the PubMed database,
but not previously reviewed and those having a historical impact
were also included. Over the past 20 years, our understanding
about genetic research has expanded together with the rapidly
advancing technology. The quality requirement for genetic studies has also evolved from candidate gene approaches, which were
often criticized for producing inconsistent and non-replicable
results (8), to more thoroughly conducted and well-powered
genome-wide studies (9). We included publications of the
Mendelian AD genes as well as publications that were referred
and curated by the National Human Genome Research InstituteEuropean Bioinformatics Institute (NHGRI-EBI) Catalog of
published genome-wide association studies (GWAS Catalog)
(10). In addition, we included high-quality association studies
reporting rare variants that meet the “analytically rigorous”
criteria for GWAS (9) or are otherwise statistically thorough.

Alzheimer’s disease (AD) is the most common form of dementia
(1) accounting for 60–80% of dementia diagnosis and affects
nearly 50 million people worldwide (2). The worldwide number
of affected individuals is expected to reach 66 million by 2030,
and 131 million by 2050 (3) as the number of older adults
increases. One in 10 people over age 65 and every third person
over age 85 in the US has a diagnosis of AD (4). The global
financial toll of dementia was estimated to be 818 billion US
dollars in 2015, an increase of 35% since 2010 and this cost is
expected to further rise together with the prevalence of AD (2).
The majority of the costs are related to family and social care of
patients, rather than medical care. About 5% of all AD patients
show cognitive symptoms before age 65 and are classified as
early onset Alzheimer’s disease (EOAD) (5). Patients showing
clinical symptoms after age 65 are classified as having late onset
Alzheimer’s disease (LOAD). Here, we provide a summary of
the clinical, neuropathological, fluid, and imaging biomarkers of
AD along with a more comprehensive review of genetic findings
in both Mendelian and sporadic forms of AD. We discuss how
genetic analysis as applied in Mendelian randomization (MR)
may be helpful in validating causality of modifiable risk factors
that could advance preventive measures. Moreover, genetic
data may be useful to facilitate precision medicine. The goal of
precision medicine is to integrate clinical, genetic, and life style
data to enable clinicians to efficiently and accurately predict the
most appropriate course of action for a patient (6). We emphasize the ways genetics may facilitate precision medicine in AD:
(1) identifying at risk individuals through risk prediction, (2)
improving diagnostic precision, and (3) expediting the discovery
of targetable disease mechanisms for drug development. Due to
the large number of published articles in biomedical research of
AD, we refer to more recent comprehensive reviews written by
domain experts and supplement these with other findings.

CLINICAL FEATURES OF AD
In 1906, the German psychiatrist Alois Alzheimer first described
the clinical features of an early-onset case of AD with its
pathognomonic hallmarks—extracellular amyloid (neuritic)
plaques and intracellular neurofibrillary tangles (NFT) (11).
Patients typically show an insidious onset and continuous
cognitive decline, which typically starts with an amnestic presentation with impaired ability to remember new information.
The cognitive decline may further affect language, reasoning,
executive function, visuospatial abilities, and the illness is often
accompanied by personality and behavioral changes that affect
the social function of the patient. In an advanced disease stage,
patients are completely dependent on their caregivers for daily
functioning such as getting dressed, toileting, mobility, and eating. The NINCDS-ADRDA criteria for diagnosing possible and
probable AD are being widely used (12) and have a sensitivity
and specificity of ~70% for distinguishing between AD patients
and people without dementia. However, they were less accurate
distinguishing between different types of dementias (13, 14).
The median survival time of patients from the symptom onset is
reported to be 9 years (15).

LITERATURE SELECTION
Our goal of writing this narrative review (7) is to discuss how
genetics may not only advance basic research on disease mechanisms but also play a role in facilitating precision medicine in
AD. We provide summaries about clinical and neuropathological
features, research on imaging and fluid biomarkers, as well as
modifiable risk factors of AD by referring to high-quality recent
systematic reviews and meta-analyses. Unpublished or original
data, submitted manuscripts, or personal communications are

NEUROPATHOLOGY OF AD
Over many years, definitive diagnosis of AD could only be made
by the “gold standard” of postmortem neuropathological examination, using a combination of CERAD score for neuritic plaques
containing amyloid beta (Aβ) (16) together with Braak staging
of NFT consisting of abnormally hyperphosphorylated tau (17).
This had been defined in the National Institute on Aging (NIA)Reagan Criteria (18). However, only half of the brains of patients
with the clinical diagnosis of probable AD showed “pure” AD
pathology (19). In 2011, the NIA and the Alzheimer’s Association
(AA) revised the diagnostic criteria aimed at integrating the
advances of imaging and cerebrospinal fluid (CSF) biomarkers to
model the three stages of AD that include preclinical stage, mild
cognitive impairment, and dementia (12, 20–22). The updated
criteria are now used in AD research and ongoing efforts exist

Abbreviations: AA, Alzheimer’s Association; Aβ, amyloid beta; AD, Alzheimer’s
disease; BMI, body mass index; CSF, cerebrospinal fluid; DIAN, Dominantly
Inherited Alzheimer Network; EOAD, early onset Alzheimer’s disease; EHR,
electronic health record; FDG, 18-fluoro-deoxyglucose; GWAS, genome-wide
association studies; LOAD, late onset Alzheimer’s disease; MR, Mendelian randomization; NFT, neurofibrillary tangles; NHGRI-EBI, National Human Genome
Research Institute-European Bioinformatics Institute; NIH, National Institute of
Health; NIA, National Institute on Aging; PD, Parkinson’s diseases; PET, positron
emission tomography; PI, physical interaction; PIB, Pittsburgh compound B; PRS,
polygenic risks score; SNP, single-nucleotide polymorphism; WES, whole exome
sequencing; WGS, whole genome sequencing.
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to refine these criteria (23). It is important to emphasize that Aβ
deposits have not been proven to be causal for late onset AD.
In addition to Aβ and NFT, other neuropathological features such
as TDP-43 immunoreactive inclusions and Lewy bodies may
coexist, along with findings like cerebral amyloid angiopathy,
cerebrovascular disease, and hippocampal sclerosis (19, 24–27).
It is important to note that AD pathologies were also found
in nearly all brain autopsies of cognitively normal individuals
above age 80, even among those considered as high-cognitive
performers (28, 29). Although some cognitively normal elderly
had severe AD pathologies, as a group, they showed less severe
AD pathologies than dementia patients. Signs of vascular injuries
ranged from 32% among high cognitive performers to 64% in late
dementia subjects.

and Aβ deposits displayed distinguishable locations with some
overlap, particularly in the association cortex, suggested that AD
is a tau-centered disease with amyloid effects.

RISK FACTORS FOR AD
Currently known risk factors for AD include age, sex, cardiovascular risk factors, metabolic risk factors, sleep apnea, family
history, and certain genetic variants (2, 4). Thus, both modifiable and non-modifiable risk factors have been associated with
LOAD risk. The non-modifiable factors include sex, aging, and
the genetic risk.

GENETICS OF AUTOSOMAL
DOMINANT AD

IMAGING AND BIOMARKERS

A recent systematic review of studies from the US, Europe,
India, and China shows that the worldwide proportion of
EOAD is around 5% of all AD cases (39). Of note, only 30–60%
of EOAD patients have a positive family history for dementia,
and about 10–14% have a family history that is consistent with
autosomal dominant inheritance (40–42). Thus, in addition
to the Mendelian disease presentation of EOAD, a substantial
proportion of EOAD cases fall into the category of sporadic
and genetically complex disease. For the Mendelian cases, three
genes that carry mutations causal for autosomal dominant AD
were identified in the 1990s, namely APP (43), PSEN1 (44),
and PSEN2 (45, 46). The APP gene encodes amyloid precursor
protein which is proteolytically processed into Aβ peptides by
β- and γ-secretase. Most pathogenic mutations in APP have
been reported to either increase Aβ production or influence
the ratio of Aβ peptides of different length (e.g., the Aβ42/Aβ40
ratio) resulting in increased self-aggregation (47). Notably, at
the same site of a disease causing APP mutation that increases
APP cleavage, a protective variant leading to a different amino
acid change was found that decreases APP cleavage (48). PSEN1
and PSEN2 genes encode part of the γ-secretase complex and
PSEN1 accounts for most of the known mutations for autosomal
dominant AD. The majority of pathogenic PSEN1 mutations
impair γ-secretase-dependent cleavage of APP and decrease the
production of both Aβ42 and Aβ40 (49). These genetic findings
in autosomal dominantly inherited EOAD (48, 50) provide
strong support for the amyloid hypothesis implicating that Aβ
plays an initiating role in AD. A recent review presented a large
body of evidence from over 25 years of research supporting the
generalizability of amyloid hypothesis (51). However, there are
also findings that contradict amyloid being the main driving
cause for the more common sporadic manifestations of AD
(52). For example, elevated amyloid deposition is frequently
found in cognitively normal subjects (28, 53–55) and CSF
level of Aβ and Aβ imaging with PIB–PET do not correlate
with cognitive decline (56). Furthermore, Aβ production is
reduced by most PSEN1 mutations (49). The anatomic and
temporal discordance between Aβ pathology, tau aggregation,
and neurodegeneration has led to the postulation of Aβ being
an initiator of a complex cascade that ends in tau-medicated
neurodegeneration (57).

To provide early and accurate diagnosis of AD, extensive efforts
have been made into developing sophisticated methods to assess
pathology in the living human brain. However, to date, no test or
combination of tests that could accurately diagnose AD is available for broad clinical use outside of AD research centers (4). CSF
levels of Aβ42, tau, and hyperphosphorylated tau (ptau) as markers for amyloid, neuronal injury, and tangles, respectively, have
been the main fluid biomarkers used in AD research (30, 31).
In CSF of AD patients, a decreased level of Aβ42 has been consistently found (32), whereas the concentrations of tau and ptau are
increased (31). Levels of CSF tau and ptau, but not Aβ42, were
found to correlate with brain atrophy in AD (33). Interestingly,
a reduction of CSF Aβ42 had been shown to correlate with brain
atrophy in non-demented elderly indicating a potential preclinical stage (33).
Unaddressed problems preventing broad clinical utility of
biomarkers include incomplete clinical validity, inconsistent
predictive value, and assay variability (34). The consensus from
experts in the field of biomarkers concludes that CSF AD biomarkers may be used alongside clinical measures to identify or
exclude AD as an underlying cause particularly in uncertain and
atypical clinical presentations (35).
In parallel to CSF biomarkers, major advances were made to
measure Aβ and tau deposits in vivo with help of brain imaging. Using a combination of 18-fluoro-deoxyglucose-positron
emission tomography (PET), which measures cerebral glucose
metabolism, and Pittsburgh compound B (PIB) PET measuring
the Aβ deposition along with CSF biomarkers, it was demonstrated that subjects with known Mendelian AD mutations have
CSF Aβ changes, brain amyloidosis, tauopathy, brain atrophy, and
decreased glucose metabolism in that same temporal order starting 20 years before the clinical onset of AD (36). More recently,
voxel-based hierarchical clustering was applied to cross-sectional
flortaucipir PET imaging for ptau and PIB–PET for Aβ in 88
elderly cognitively normal individuals (37). The study identified
four tau clusters and four Aβ clusters based on spatial features.
It shows that tau clusters map to the temporal lobe and orbitofrontal cortex and expand to parietal and frontal lobes roughly
corresponding to Braak tau stages (38), whereas Aβ deposits are
dispersed in widespread heteromodal cortex. The finding that tau
Frontiers in Medicine | www.frontiersin.org
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individuals. We have previously reported a homozygous APOE4
carrier who reached the age of 95 years without overt signs of
dementia (65).
APOE encodes a lipid carrier Apolipoprotein E (ApoE) that
is found both in the periphery and the central nervous system
(66). The risk effects of APOE4 in AD were linked to ApoE’s
pleiotropic functions that lead to reduced cholesterol transport,
less efficient Aβ clearance and more aggregation, triggering
neurotoxicity through Tau phosphorylation, increased brain neuronal activity and atrophy, reduced synaptic plasticity, and greater
neuroinflammation. The large body of literature investigating
the functional mechanism of ApoE in AD has been recently
summarized (67–69). Most recently, ApoE has been shown to
affect tau pathogenesis, neuroinflammation, and tau-mediated
neurodegeneration independently of amyloid-β pathology in
transgenic mice (70).
In addition to the well-established effects of APOE, GWAS
have identified more than 30 genomic loci that are associated
with AD risk. Unlike the APOE variants, the majorities of GWAS
identified risk variants do not alter the protein sequence and are
not necessarily the actual causal variants. Instead, an associated
variant may be in linkage disequilibrium with an unidentified
causal variant that may alter protein sequence, splicing patterns,

For the majority of AD patients, no known causal genetic mutations have been identified. LOAD as well as many cases of EOAD
are genetically complex and have multifactorial causes, which is
similar to other chronic common diseases. A large populationbased twin study estimated that genetic factors contribute
58–79% of etiologic role for LOAD (58). More than 20 years ago,
APOE4 (also called APOE ε4) allele of the APOE gene has been
identified as a major genetic risk factor for LOAD (59, 60). The
APOE gene has two missense variants at amino acid residues 112
and 158 leading to three common haplotypes, which are typically
referred to as APOE alleles ε2 (Cys and Cys), ε3 (Cys and Arg),
and ε4 (Arg and Arg). Among Caucasians, homozygous ε4 carriers show the highest life time risk for AD (68–91%) (61–64)
with an odds ratio (OR) of 11–12.9 compared with homozygous
ε3 carriers. Individuals carrying one copy of ε4 have a threefold
risk increase for AD compared with people having no ε4 allele,
and the ε2 allele is protective against AD (Figure 1). In AfricanAmericans and Hispanic populations the OR of APOE4 is found
to be less pronounced compared to Caucasians. It is important to
note that unlike the mutations in autosomal dominant forms of
AD, APOE4 is not a sufficient determinant of AD even in old aged

Figure 1 | Effect sizes of AD associated variants for the respective minor alleles. The red dotted line indicates OR = 1 [log(OR) = 0]. Minor alleles with log(OR)
above the line are risk alleles and below the line are protective. Abbreviations: APOEe4(hom), homozygosity for the APOE4 allele; APOEe4(het), heterozygosity for
the APOE4 allele; ABCA7-LoFs, aggregated effects of loss-of-function variants in ABCA7; OR, odds ratio; AD, Alzheimer’s disease.
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or gene expression. In GWAS for LOAD, genes that are located
near the associated variants are considered potential risk genes,
but further evidences are necessary to support their actual
etiological role. As of September 1, 2017, the NHGRI-EBI GWAS
Catalog (10) listed 74 published GWAS studies on LOAD. We
manually curated this list by merging multiple reports for the
same locus into one row (Table 1). It is clear that some gene loci
have been replicated by two or more GWAS or meta-analysis.
These genes are BIN1, CD2AP, CLU, CR1, EPHA1, MS4A4E/
MS4A6A, PICALM, and TREM2. The confidence for these genes
to be actual AD genes is higher compared with those genes
supported by a distant variant in one single study. For example,
one association signal on Chromosome 2 was supported by an
intergenic variant rs17034806 that is located 200 kb from the gene
RANBP2 (71). In Table 1, if a locus is implicated in more than one
association study or is supported by meta-analysis, we show the
strongest association signal.
Although GWAS have been a powerful method to uncover
risk loci in AD, they are less suitable to discover infrequent or

rare variants. A recent estimate indicates that only 30.6% of the
genetic variance can be explained by known AD single-nucleotide
polymorphisms (SNPs), but a sizeable fraction of the unidentified
risk variants may be located close to the known risk SNPs, potentially as rare variants (72). Consistent with an important role of
rare variants, our investigation using whole genome sequencing
(WGS) showed an increased burden of rare loss-of-function variants in immune genes in AD compared with cognitively healthy
centenarians (73). Large-scale sequencing, such as whole exome
sequencing (WES) and WGS, has already identified new genes
that harbor rare variants typically missed by GWAS. Rare variants that increase the risk for AD have been identified in TREM2
(74, 75), PLD3 (76, 77), UNC5C (78), AKAP9 (79), ADAM10 (80),
and ABI3 (81). Moreover, the burden of rare coding variants in
risk genes identified by GWAS such as ABCA7 (82–84) as well as
in Mendelian genes for AD had been found to be increased among
LOAD patients compared with unaffected general population
(85, 86). The potential impact of rare variants in AD is further
underscored by rare and low-frequency protective variants such
as APOE2 allele (61, 67), APP A673T (48), and PLGC2 P522R
(81). The effect sizes of both GWAS loci and genes harboring
reported rare AD-associated variants are presented in Figure 1.
Undoubtedly, the search for rare risk variants with higheffect sizes for LOAD faces many obstacles. First, many studies
are underpowered to separate true signals from false-positive
associations as tens of thousands of cases and controls are usually
required to achieve genome-wide significance level of P < 5E−8.
Second, allele frequencies of rare variants are more likely to vary
between population cohorts of different ethnic backgrounds
due to founder effects, making replication studies difficult to
conduct. For example, risk allele frequencies in PLD3 in controls
of one cohort may be higher than that of cases in another cohort,
while combined result may be nominally significant (77) or not
significant at all (87–89). Third, the necessarily small number of
carriers of rare variants makes the respective association studies
particularly prone to be impacted by factors such as age, APOE4
carrier status, and different genotyping and sequencing platforms.

Table 1 | AD associated loci from the NHGRI-EBI GWAS Catalog.
CHR

Region

Gene locus

1
2
2
2
5
5
5
6

1q32.2
2q13
2q14.3
2q37.1
5p15.1
5q14.3
5q31.3
6p21.32

6
6
6
7
7
7
7
8
8
10
10
11
11
11
11
13
14
14
17
17
19
19
19
20

6p21.1
6p12.3
6q25.1
7p14.1
7p12.1
7q22.1
7q35
8p21.2
8p21.1
10p14
10p13
11p11.2
11q12.2
11q14.2
11q24.1
13q33.1
14q22.1
14q32.12
17q22
17q25.1
19p13.3
19q13.32
19q13.41
20q13.31

CR1
RANBP2
BIN1
INPP5D
FBXL7
MEF2C
PFDN1, HBEGF
HLA-DRB5,
HLA-DRB1
TREM2
CD2AP
MTHFD1L
NME8
COBL
ZCWPW1
EPHA1
PTK2B
CLU
USP6NL, ECHDC3
FRMD4A
CELF1
MS4A4E/MS4A6A
PICALM
SORL1
SLC10A2
FERMT2
SLC24A4, RIN3
BZRAP1
ATP5H, KCTD2
ABCA7
APOE
CD33
CASS4

Risk allele
frequency

P-value Risk allele
OR

0.197
0.08
0.409
0.488
0.92
0.592
0.5
0.276

6.0E−24
4.0E−08
7.0E−44
3.0E−08
5.0E−08
3.0E−08
7.0E−09
3.0E−12

1.18
1.76
1.22
1.08
1.59
1.08
1.08
1.11

0.0063
0.27
0.07
0.627
0.991
0.713
0.662
0.366
0.621
0.4
0.028
0.316
0.597
0.642
0.961
0.985
0.092
0.783
0.6
0.09
0.19
0.15
0.7
0.917

2.0E−12
9.0E−09
2.0E−10
5.0E−09
4.0E−08
6.0E−10
1.0E−13
7.0E−14
3.0E−25
3.0E−08
1.0E−10
1.0E−08
6.0E−16
9.0E−26
1.0E−14
5.0E−08
8.0E−09
6.0E−09
4.0E−08
4.7E−09
1.0E−15
2.0E−157
2.0E−09
3.0E−08

2.9
1.11
2.1
1.08
3.59
1.1
1.11
1.1
1.16
1.08
1.68
1.08
1.11
1.15
1.30
2.68
1.14
1.1
1.09
1.53
1.15
2.53
1.1
1.14

PATHWAYS IMPLICATED BY RISK GENES
FOR AD
The established AD associated genes exert pleiotropic functions
across many molecular pathways. Several of these pathways stand
out by providing insights for the disease mechanisms that may
play a role in the etiology of AD (90–92). Major pathways include
inflammatory response (ABCA7, CD33, CLU, CR1, MS4A,
INPP5D, TREM2, PLCG2, PTK2B, and ABI3), lipid metabolism
(APOE, CLU, ABCA7, and PLCG2), as well as endocytosis/
vesicle-mediated transport (BIN1, PICALM, CD2AP, EPHA1,
and SORL1). Other functional categories include regulation of
cell cycle (RANBP2), oxidative stress response (MEF2C), and
axon guidance (UNC5C).
A role of innate immunity and inflammation in AD etiology is
independently supported by a large body of functional evidence
(93–95). Among the risk genes from the immune pathways,
TREM2 stands out with its high effect-size of AD risk (74, 75).
TREM2 stands for triggering receptor expressed on myeloid

The database was queried on September 1, 2017 for association studies on AD. If an
association locus is reported by multiple GWAS, we merged the results by reporting
the most significant P-value for that locus.
CHR, chromosome; OR, odds ratio; AD, Alzheimer’s disease; GWAS, genome-wide
association studies; NHGRI-EBI, National Human Genome Research Institute-European
Bioinformatics Institute.
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cells 2, a single-transmembrane protein expressed by monocytic
myeloid cells. Both ApoE and Clusterin (encoded by CLU)
are extracellular chaperons that prevent protein aggregation.
In addition, both bind to the microglial receptor TREM2 and thus
may promote uptake of Aβ by microglia (96). Studies on animal
and human brains indicated that the TREM2 risk variant p.R47H
impairs TREM2 detection of lipid ligands leading to microglia
dysfunction (97, 98). In addition to TREM2, the two newly
identified AD risk genes ABI3 and PLCG2 are highly expressed
in microglia as well (81).
The abundance of genomics data in the public domain can
be utilized not only to confirm the known connections among
AD genes but also to reveal potentially new genes involved in the
disease. Figure 2 shows an example of a network representation
of AD genes by the GeneMANIA software tool (99). AD genes, as
well as other genes deemed to be appropriate by the program, can

be linked by criteria such as coexpression, physical interaction
(PI) studies, or being part of the same pathway. Figure 2 shows
an example of visualization of PI and pathways of a subset of AD
genes reviewed in this article. The known high impact AD genes
(APP, APOE, PSEN2, and PSEN1) are also highly connected
genes. New genes introduced by this program may be further
investigated as potential candidate genes for AD. As the computational methods to integrate larger biological data sets continue
to improve and be refined, known risk genes may predict gene
sets (100) and pathways that can be targeted by drugs.

POLYGENIC RISK SCORES
Because many AD risk SNPs are common variants, every
individual necessarily inherits multiple such risk alleles. A
polygenic risks score (PRS) (101) can be calculated based on the

Physical Interacons

Pathway

Figure 2 | GeneMania network for physical interaction (PI) and pathway. An example of GeneMANIA network when only the PI and pathway links are used.
Alzheimer’s disease genes from input list are presented as large black circles, and other genes deemed to be associated with the cluster are small black circles.
Genes not linked to the main cluster are discarded.
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number of common genetic risk factors present in an individual’s
genome, which may be used as predictor for AD risk (102, 103).
Using the area under the curve receiver operator characteristic
method, PRS may capture nearly all of the genetic liability from
common risk variants for AD. However, the efficacy of a genetic
predictor is dependent on prevalence and heritability of a disease (104). In AD, the prevalence is highly dependent on age.
For the younger age group (65–74) PRS profile captured 90%
of the phenotypic variance that can be attributed to common
SNPs, which was estimated to be about 24%. Even though it is
still controversial whether PRS is a good enough predictor for
clinical use (105, 106), it may be useful to identify high-risk
subjects where disease prevention studies can focus.

interventional trial (111) along with observational studies
(112–117) supports the notion that physical activity may reduce
dementia risk. However, a recent meta-analysis of several randomized controlled trials (118) does not support the beneficial
effects of long-term exercise on dementia or cognitive decline.
A recent large trial with random assignment of intensive lifestyle intervention over 10 years showed that sustained relative
weight loss and increases in physical activity did not alter the
subsequent prevalence of cognitive impairment in diabetic and
obese patients (119). It is currently uncertain whether life style
intervention would prevent AD.
Another method to address the causal relationship of a potential modifiable risk factor (exposure) with an outcome such AD is
MR. MR infers causation between the exposure and the outcome
if the genetic variants associated with the exposure are also associated with the outcome. In other words, if a clinical risk factor
P1 is causal for a disease P2, then genetic risk variants G associated with P1 would also be associated with P2 (G → P1 → P2)
(120, 121). In principle, MR is expected to avoid bias from
reverse causation and generally reduce confounding from other
modifiable environmental exposures as it is a common problem
in observational studies. Thus, it may provide relatively unbiased
estimates of the effect of the modifiable risk factor being studied
(122). A limitation of the MR approach is that at least one genetic
variant that can reliably predict the exposure is required.
Larsson et al. (123) applied MR on genetic data from over
17,000 AD cases and over 37,000 controls to analyze the effect
of 24 potentially modifiable risk factors. Assuming linear
association and absence of any alternative causal pathways,
genetically predicted higher educational attainment was found
to significantly lower odds for AD. This finding is consistent
with observational studies. Surprisingly, suggestive evidence was
also found for genetically predicted higher quantity of cigarette
smoking and lower odds of AD, which is inconsistent with results
from cohort studies (124). In addition, genetically predicted
higher 25-hydroxyvitamin D concentrations were associated
with decreased AD odds, whereas higher coffee consumption
with increased odds. Genetically predicted alcohol consumption,
serum folate, serum vitamin B12, homocysteine, cardiometabolic
factors, and C reactive proteins were not predicted to influence
AD risk. One limitation of this study is that the authors used
summary of association results rather than actual genotypes.
Another MR study using different intermediate factors on the
same set of GWAS data found that genetically predicted higher
systolic blood pressure may be protective for AD (125), which is
compatible with the reported protective effect of higher diastolic
blood pressure (110). This result is nonetheless counterintuitive,
given the known detrimental health effects of hypertension. This
study also found a protective effect of genetically predicted higher
smoking quantity. In addition, findings on cholesterol were not
consistent with a causal effect on AD risk, after controlling for
the confounding effect of APOE. Clearly, more research on larger
datasets that include recorded clinical and lifestyle factors are
needed to confirm or reject causal implications of some modifiable risk factors of AD.
In addition to the MR approach, there are other attempts
to find interplay between genetic and environmental factors.

MODIFIABLE RISK FACTORS FOR AD
Observational studies have suggested that diabetes, mid-life
obesity, mid-life hypertension, high cholesterol, and smoking are
modifiable risk factors for AD (107). In terms of modifiable protective factors, education has been robustly shown to reduce AD
risk (108). However, for many modifiable factors, no consistent
pattern was found across studies (109). A recent comprehensive
meta-analysis of 93 modifiable risk factors was conducted from
323 retrospective case/control and prospective cohort studies,
which were selected after a systematic review of 16,906 publications (110). This study analyzed associations between AD risk
and medical, dietary and occupational exposures as well as serum
biochemistry, preexisting diseases, lifestyle, and psychological
factors. The identified potentially protective factors include medical exposures of estrogen, statin, antihypertensive medications,
and non-steroidal anti-inflammatory drugs, along with dietary
exposures to folate, vitamin E/C, and coffee. Other potentially
beneficial factors include a history of arthritis, heart disease, and
cancer, cognitive activity, current smoking (in Western population), light-to-moderate drinking, and stress. Factors associated
with increased risk were hyperhomocysteinemia, depression,
frailty, carotid atherosclerosis, hypertension, low diastolic blood
pressure, and low education. Evidence for metabolic factors
appeared to be inconsistent. Notably, type 2 diabetes mellitus was
associated with increased risk in an Asian population, but metabolic syndrome was associated with decreased risk. Moreover,
both high body mass index (BMI) in mid-life and low BMI in
late-life were associated with increased risk. Most recently, the
Lancet Commissions estimated the population attributable
fraction of the following modifiable risk factors: hearing loss
(9.1%), “less education” (7.5%), followed by smoking, depression,
physical inactivity, social isolation, hypertension, diabetes, and
mid-life obesity in a declining order (2). The authors estimated
that about 35% of total dementia risk may be attributable to a
combination of these risk factors. Any preventive interventions
addressing these factors can be applied independently of the
presence of other factors like genetic risk. However, identifying
individuals who would benefit most from a certain intervention
due to their genetic risks remains an open question.
It has been widely hypothesized that factors such as physical
activities that protect cardiovascular health would also protect the brain from AD and other dementias. A prospective
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An example is to study gene–environment interactions (126)
and one study have shown that estrogen use may be associated
with less cognitive decline among APOE4 negative women (127).

implement, due to its invasiveness, high cost, and limited availability of equipment. Other fluid biomarkers have been useful
in research studies (21), but their broad use in clinical settings
was limited due to lack of established reproducible assays and
the reluctance of patients to agree to lumbar puncture procedure
(140). Most recently, reports on high-performance plasma
amyloid-β biomarkers showed promising accuracy in predicting
brain amyloid-β burden (141). Unlike these biomarkers, known
genetic risks of a subject remain stable over time and are not
influenced by any confounding factors. Currently, genetic risk
factors can be assessed at a very low cost starting at around $50
per sample for array-based genotyping data. These arrays cover
common variants that may include disease risk variants, which
can be further used to impute additional disease risk variants.
Moreover, the cost for more comprehensive WES and WGS is
down trending toward several hundred dollars. Thus, it is feasible
that genetic risk profiles may be used alone or combined with
other biomarkers to select at risk subjects in preclinical stage for
closer follow-ups and enrollment into preventive studies.
Genetic testing may also increase diagnostic precision in
patients with dementia. A recent study showed that known
pathogenic mutations for AD and frontotemporal dementia were
found with similar proportion in familial LOAD and sporadic
LOAD patients. Mutations for Parkinson’s diseases (PD) and
amyotrophic lateral sclerosis were also found in clinically diagnosed AD subjects (86). Therefore, genetic testing may prevent
other neurodegenerative diseases, which may even have some
treatment options, from being misdiagnosed as AD. Combined
with fluid and imaging biomarkers, genetics may further increase
diagnostic accuracy to ensure clinical trials are done in truly AD
patients. Furthermore, instead of treating AD as a homogeneous
disease, genetics and other diagnostic methods hold the potential
to identify functional disease subtypes that could be specifically
targeted.
Another advantage of genetic screening, especially in subjects
with family history of dementia, would be the improved risk
assessment. An accurate risk assessment could lead to specific
consultation for preventive measures addressing modifiable risk
factors, such as early use of hearing aids and managing metabolic
symptoms. Linking genomic data and electronic health record
(EHR) may further help researchers to identify how genetic
factors interact with other health conditions such as the impact
of medication use on disease risk. For example, an EHR-based
analysis found that salbutamol, a β2-adrenoreceptor agonist often
prescribed for asthma, is associated with a 34% lower risk of PD
and propranolol, a drug frequently prescribed for hypertension,
with increased risk (142). Similar approaches of EHR mining may
discover medications that alter AD risk. Genetic risk factors had
strongly supported a role of immune pathways in AD. Analysis
of large EHR data could find out whether drugs that target the
immune system had an impact on risk for AD.
Large-scale genetic testing may come from consumer genetic
services as they become more broadly available. More than three
million people already had their DNA tested at 23&Me and
received their carrier status of APOE4 among other risk variants
affecting health. Currently, there are hundreds of companies
offering similar services and the list is growing (143). The number

CURRENT STATE OF DEVELOPMENT
OF TREATMENT FOR AD AND FUTURE
OUTLOOK
Currently, no disease modifying treatment is available for AD.
The only treatments available are treating symptoms, but not the
causes of the disease and its progression (128). This statement
holds despite the stunning fact that between 2002 and 2014, more
than 400 drug trials for AD have been performed but subsequently
failed (129). More recently, several large drug trials aiming at
reducing the amyloid burden had failed to show efficacy. Attempts
to reduce Aβ production (130) as well as immunotherapeutic
approaches to clear amyloid plaques from the brain did not show
efficacy in slowing down or halting the course of AD (131, 132).
Biogen’s immunotherapeutic drug Aducanumab reported positive Phase 1 results on removing brain Aβ plaques and clinical
benefits (133). The result of a larger phase 3 trial is still pending.
Explanations of the failure of so many drug trials targeting Aβ
argue for possible flaws in the amyloid hypothesis, or the possibi
lity that the disease being too advanced at the time of intervention
(131, 134). Drug trials in presymptomatic mutation carriers of
autosomal dominant AD may shed light on whether targeting
amyloid will yield any therapeutic effect (135). Ongoing drug
trials include targeting anti-amyloid, anti-tau, anti-inflammatory,
neuroprotection, stem cell therapy, and metabolism (136).
Advances of information technology have enabled health
care providers to collect, store, and analyze large quantities of
individual health data ranging from clinical information such
as diagnostic test results and medication history to lifestyle factors such as smoking. At the same time, scientific community is
equipped with methods to generate, process, and analyze large
datasets from genomics, imaging, transcriptomics, and many
other data-intensive researches. The current concept of precision
medicine (137) considers clinical, behavioral, and molecular
data to predict personalized disease risk, implement preventive
measures, make more accurate diagnosis, and recommend treatments that maximize therapeutic effects and minimize adverse
effects. To facilitate precision medicine the National Institute of
Health (NIH) launched the All of Us research program, which
plans to enroll one million participants (https://allofus.nih.gov/
about/about-all-us-research-program).
Under the assumption that the treatment success of a potentially
effective pharmacological intervention depends on its initiation
in the presymptomatic stage, the identification of at risk subjects
will be crucial to maximize treatment effect. Currently, a prevention trial as part of the Dominantly Inherited Alzheimer Network
(DIAN) is under way (138). However, results from DIAN may
not be representative for the majority of at risk subjects, as most
AD patients do not carry Mendelian mutations. Independently,
imaging amyloid and tau was shown to identify such at risk subjects (139). In reality, however, large-scale application of imaging
biomarkers as a broad population screening method is difficult to
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research (as discussed above) is graphically described in Figure 3.
Of course, large-scale population level genetic testing also brings
ethical challenges. Clinicians and researchers need to take into
account the respective guidelines for genetic testing (147).
Current studies indicate that the majority of individuals tested
for autosomal dominant forms of AD under a standardized counseling protocol demonstrated effective coping skills. Negative
psychological reactions were absent after several months and
the testing was perceived to be beneficial. The potential benefits,
harms, and dilemmas of genetic testing and impacts on family
members were detailed in a case report (148). If results of risk
factors are returned to the participants, counseling needs to be
provided and psychosocial support should be made available.
It is important that patients and customers of consumer genetics
services understand that typical risk factors are not deterministic
for AD. The ethical, legal, and social implications of genetic
testing such as testing-induced harm and discrimination are an
active area of research at NIH (149).
In summary, the current approach for AD consists of optimi
zing modifiable risk factors to reduce and delay symptom onset
as well as symptomatic treatment after disease onset. The dawn
of the big data era may make it feasible to advance precision

of people equipped with personal genetic data will likely continue
to increase in the general population. Such consumer genetic data
may be integrated into EHR to assist diagnostic assessments and
choice of treatment. For example, clinicians may consider avoiding propranolol and other β-blockers for patients with genetic
predisposition for PD.
In addition to risk variants, genetic studies will identify more
protective variants against AD. As the sample size becomes larger,
researchers may identify potentially protective factors in subjects
who carry strong risk factors such as homozygosity of APOE4,
but do not develop AD at an advanced age (65). Identification of
protective variants in such a population may lead to possible new
drugs that act through a similar mechanism. A recent example for
protective genetic variants fueling new effective therapeutics was
the development of PCSK9 inhibitor for hypercholesterolemia
(144, 145). The newly identified gene PLCG2 that harbors rare
protective variants is highly expressed in microglia and may be
a target to be exploited for drug discovery in AD (81). Certainly,
a hope is that ongoing sequencing efforts (146) would identify
more protective variants that can be targeted by drugs.
A workflow for clinical translational research implementing clinical assessments, genetics, and biomarkers into clinical

Figure 3 | Precision medicine approach for dementia. This is a graphical outline of how genetic and genomic information could be combined and integrated with
electronic health records (EHRs) to improve the accuracy of dementia diagnosis and facilitate drug discovery. Middle-aged and older people (e.g., age > 50) are
enrolled in an ongoing protocol that includes medical and family history, diagnostic assessment, and access to EHR. For those who have signs of cognitive
impairment, genetic testing using either mutation-panels, genotyping arrays, whole exome sequencing or whole genome sequencing depending on the clinical
question is performed alongside biomarkers. If a dementia diagnosis is confirmed through genetics and biomarkers, the patients are referred to specialized
behavioral and pharmacological intervention and have the option to participate in drug trials. For the majority of subjects who do not have definitive biological
findings, a likelihood risk score may be estimated based on the genetic and biomarker profiles. These risk scores may provide support for clinical diagnosis and
identify subjects at risk for dementia. The presymptomatic at risk subject may be enrolled in longitudinal studies on prevention and those who never develop
dementia despite having high risk may be studied to identify protective factors.
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medicine by systematically integrating massive biological data
generated by next-generation genomic sequencing, biomarker
testing, and EHRs. This development is likely to shed more light
to the complex biology of AD and accelerate development of better prevention, diagnosis, and treatments.
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